相关实验视频

Updated: Mar 3, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

眼睛高血压的患病率和危险因素随着氨酸 (Iluvien®) 内膜注射:SAFAC研究

Yasmine Serrar¹, Lucas Sejournet^1,2, Benoît Allignet^3,4

¹Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, 103, Grande Rue de la Croix-Rousse, 69317, Lyon Cedex 04, France.

Ophthalmology and therapy

|March 1, 2026

概括

眼睛高血压 (OHT) 影响约25%的患者在注射氨胺植入物 (FAc-I) 后. 年轻的年龄和之前的OHT或青光眼是关键的危险因素,需要定期监测眼内压力.

科学领域:

眼科医生眼科眼科
视网膜疾病视网膜疾病
视光眼管理视光眼管理

背景情况:

素乙胺植入物 (FAc-I) 用于治疗各种形式的斑点.
眼睛高血压 (OHT) 是皮质类固醇治疗的潜在副作用,包括FAc-I.
了解FAc-I后OHT的患病率和风险因素对于患者管理至关重要.

研究的目的:

为了确定眼睛高血压 (OHT) 的患病率,在静脉内氨醇乙胺植入物 (FAc-I) 注射后.
为了确定与FAc-I治疗后OHT发展相关的风险因素.
为了评估治疗后FAc-I OHT的有效性.

主要方法:

对接受至少一次FAc-I注射的患者进行了回顾性单心研究.
OHT定义为眼内压力 (IOP) ≥25 mmHg和/或比基线增加≥10 mmHg.
分析患者人口统计,斑点的病因和治疗结果.

主要成果:

在接受FAc-I治疗的眼睛中,OHT发生在24.6%的眼睛中,不论是底层疾病.
年轻的年龄和先前存在的OHT或青光眼被确定为OHT发展的重要风险因素.
大多数OHT病例通过局部药物 (57%的OHT病例) 或选择性激光形造形 (7.0%) 成功管理.

结论:

眼睛高血压是FAc-I注射后的常见并发症,影响大约四分之一的患者.
年轻的患者和有OHT或青光眼病史的人面临更高的风险.
对接受FAc-I的患者,特别是那些具有已确定的风险因素的患者,定期进行IOP监测至关重要.

关键词:

皮质类固醇静脉内注射注射氨基醇乙化物植入物植入物眼睛高血压是什么意思

更多相关视频

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...